Moderna company headlines, earnings, strategy, leadership, and market-moving business updates.
Market data may be delayed. For informational purposes only. Not investment advice.
A market report says an mRNA treatment developed by Moderna in combination with Merck’s Keytruda achieved success in a Phase 3 cancer trial, a milestone investors track closely for what could be one of the first mRNA vaccines to reach that late-stage bar in oncology.
THE APEX TIMES
THE APEX TIMES
Major U.S. indexes moved higher as traders weighed upcoming Federal Reserve minutes and Treasury buyback activity. Moderna shares rallied sharply after fresh cancer-related drug news circulated.
THE APEX TIMES
Late-morning trading in the U.S. saw major indexes move higher after the Treasury moved to lift a cap on buybacks of long-dated securities. In healthcare, Moderna and Merck pointed to positive outlines from a melanoma vaccine clinical trial, saying a primary endpoint was met, according to market coverage.
THE APEX TIMES
The biotech said an experimental mRNA-based cancer therapy cleared a key early step in a study that it expects could be the first of its kind if regulators approve it. Moderna and partner Merck were both referenced in the update.
THE APEX TIMES
Moderna and Merck & Co said their personalized mRNA cancer vaccine, intismeran, when combined with Keytruda, slowed melanoma recurrence and spread in a late-stage trial, sending Moderna shares higher.
THE APEX TIMES
U.S. stocks climbed Wednesday as investors weighed government debt buybacks ahead of Federal Reserve minutes. Shares of Moderna moved higher on reports tied to cancer drug developments, while bitcoin also extended gains.
THE APEX TIMES
A trial update involving Moderna and Merck for a melanoma vaccine helped lift Moderna’s stock, with the announcement described as a “landmark moment” in treatment for one of the deadliest forms of skin cancer.
THE APEX TIMES
Moderna’s stock jumped after a late-stage study of a cancer vaccine, developed with Merck, reported successful results in patients with melanoma, a development investors treated as a meaningful step forward for the drug program.
THE APEX TIMES
The jump follows market coverage claiming Moderna’s mRNA cancer vaccine, in collaboration with Merck, posted the first-ever positive Phase 3 outcome for the program.
